Technology
Alterity Therapeutics to commercialise technology that breaks antibiotic resistance – Small Caps
The University of Queensland’s commercial vehicle UniQuest has granted a licence allowing Alterity Therapeutics (ASX: ATH) to use its zinc ionophore technology…
The University of Queenslands commercial vehicle UniQuest has granted a licence allowing Alterity Therapeutics (ASX: ATH) to use its zinc ionophore technology in combating superbugs.
UniQuest has given Alterity exclusive worldwide rights to use its zinc ionophore technology in developing and commercialising therapies that re-sensitise bacteria to antibiotics.
Once Alterity has begun receiving commercial revenue from commercialising the technology, it will make milestone and royalty payments to UniQuest…
-
General12 hours agoTaylor Swift breaks Adele’s record for most album sales in first week
-
Business24 hours agoCould a small investor today match the historic returns of Warren Buffett?
-
General17 hours agoMan charged with murder after alleged assault victim dies in Hervey Bay
-
Noosa News16 hours agoPublic health alert for nitazenes issued after person dies in Queensland